Astellas to halt work at R&D subsidiary amid restructuring plan

Astellas Pharma has begun restructuring its operations, with plans to discontinue all work at its R&D subsidiary of about 200 employees by March 2019. An early retirement incentive program is esti…
Read the full story: FierceBiotech: Biotech